Comparison of dopamine with levodopa in the induction of aryl sulfotransferases and estrogen sulfotransferase in rat liver

doi:10.5246/jcps.2014.07.062

Journal of Chinese Pharmaceutical Sciences ›› 2014, Vol. 23 ›› Issue (7): 471-479.DOI: 10.5246/jcps.2014.07.062

• Original articles • Previous Articles Next Articles

Comparison of dopamine with levodopa in the induction of aryl sulfotransferases and estrogen sulfotransferase in rat liver

Xueyan Shao¹, Jian Li¹, Siyuan Wang¹, Guangping Chen³, Jiaojiao Xu¹, Xiwei Ji¹, Liang Li¹, Wei Lu^1,2, Tianyan Zhou^1,2*

1. Department of Pharmaceutics, School of Pharmaceutical Science, Peking University Health Science Center, Beijing 100191, China
2. State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center, Beijing 100191, China
3. Department of Physiological Sciences, Center for Veterinary Health Sciences, Oklahoma State University, Stillwater OK74078, USA

Received:2014-04-04 Revised:2014-05-13 Online:2014-07-18 Published:2014-05-25
Contact: Tel.: 86-10-82805937, Fax: 86-10-82801717
Supported by:
National Natural Science Foundation of China (Grant No. 81072699).

Abstract

Abstract:

Sulfotransferases (SULTs) are one of the most important phase IIdrug-metabolizing enzymes. Among them, aryl sulfotransferases (SULT1A1) and estrogen sulfotransferase (EST, SULT1E1) belong to the rSULT1family that catalyzes sulfation of phenoliccompounds. Dopamine (DA) acts as a vital neurotransmitter in central nervous system(CNS) and regulates a variety of activities in periphery. In our study, we aim to detect the effects of exogenous DA and levodopa (L-DOPA) on rSULTs (rSULT1A1 and rSULT1E1) in rat liver. In order to achieve this target, varying doses of DA (0, 2, 10 and 100 mg/kg/d) and L-DOPA (0, 5, 25 and 125 mg/kg/d) were provided to male and female rats, respectively. Real-time PCR assay and western blot were used in the determination of the mRNA and protein expression of rSULTs. PNPS assay and radioactivity assay were applied to the detection of enzyme activity of rSULT1A1 and rSULT1E1, respectively. Our results showed that DA inducedthe expression and activity of rSULT1A1 in the liver of male and female rats and DA had little effect on rSULT1E1. However, L-DOPA caused no evident change of rSULT1A1 in both sex and had no significant effect on rSULT1E1 in female rat liver, but increased rSULT1E1 expression and activity only in male rat liver when administered at high dose. Our results suggest that DA plays different roles in the regulation of rSULT1A1 and rSULT1E1 when it is in periphery or in the CNS.

Key words: Dopamine, Levodopa, Dopamine receptors, Sulfotransferase, Induction

CLC Number:

R962

Supporting:

Xueyan Shao, Jian Li, Siyuan Wang, Guangping Chen, Jiaojiao Xu, Xiwei Ji, Liang Li, Wei Lu, Tianyan Zhou. Comparison of dopamine with levodopa in the induction of aryl sulfotransferases and estrogen sulfotransferase in rat liver[J]. Journal of Chinese Pharmaceutical Sciences, 2014, 23(7): 471-479.

References

[1] Bidwell, L.M.; McManus, M.E.; Gaedigk, A.; Kakuta, Y.; Negishi, M.; Pedersen, L.; Martin, J.L. J. Mol. Biol. 1999, 293, 521-530.

[2] Gamage, N.; Barnett, A.; Hempel, N.; Duggleby, R.G.; Windmill, K.F.; Martin, J.L.; McManus, M.E. Toxicol. Sci. 2006, 90, 5-22.

[3] Suzuki, T.; Miki, Y.; Nakamura, Y.; Ito, K.; Sasano, H. Mol. Cell Endocrinol. 2011, 340, 148-153.

[4] Duanmu, Z.; Kocarek, T.A.; Runge-Morris, M. Drug Metab. Disp. 2001, 29, 1130-1135.

[5] Runge-Morris, M.; Kocarek, T.A.; Falany, C.N. Drug Metab. Rev. 2013, 45, 15-33.

[6] Dooley, T.P; Haldeman-Cahill, R.; Joiner, J.; Wilborn, T.W. Biochem. Biophys. Res. Commun. 2000, 277, 236-245.

[7] Rainey, W.E.; Carr, B.R.; Sasano, H.; Suzuki, T.; Mason, J.I. Trends Endocrinol. Metab. 2002, 13, 234-239.

[8] Pasqualini, J.R. Annals of the New York Academy of Sciences. 2009, 1155, 88-98.

[9] Coughtrie, M.W. Pharmacogenomics J. 2002, 2, 297-308.

[10] Falany, C.N. FASEB J. 1997, 11, 206-216.

[11] Weinshilboum, R.M.; Otterness, D.M.; Aksoy, I.A.; Wood, T.C.; Her, C.; Raftogianis, R.B. FASEB J. 1997, 11, 3-14.

[12] Beaulieu, J.M.; Gainetdinov, R.R. Pharmacol. Rev. 2011, 63, 182-217.

[13] Wojcikowski, J.; Golembiowska, K.; Daniel, W.A. Curr. Drug Metab. 2007, 8, 631-638.

[14] Missale, C.; Nash, S.R; Robinson, S.W.; Jaber, M.; Caron, M.G. Physiol. Rev. 1998, 78, 189-225.

[15] Zhang, X.; Guo, H.; Xu, J.; Li, Y.; Li, L.; Zhang, X.; Li, X.; Fan, R.; Zhang, Y.; Duan, Z.; Zhu, J. Transl. Res. 2012, 159, 407-414.

[16] Sarkar, C.; Chakroborty, D.; Chowdhury, U.R.; Dasgupta, P.S.; Basu, S. Clin. Cancer Res. 2008, 14, 2502-2510.

[17] Moreno-Smith, M.; Lu, C.; Shahzad, M.M.; Pena, G.N.; Allen, J.K.; Stone, R.L.; Mangala, L.S.; Han, H.D.; Kim, H.S.; Farley, D.; Berestein, G.L.; Cole, S.W.; Lutgendorf, S.K.; Sood, A.K. Clin. Cancer Res. 2011, 17, 3649-3659.

[18] Fahn, S. Mov. Disord. 2008, 23, S497-508.

[19] Karthik, S.; Lisbon, A. Semin. Dial. 2006, 19, 465-471.

[20] De Backer, D.; Biston, P.; Devriendt, J.; Madl, C.; Chochrad, D.; Aldecoa, C.; Brasseur, A.; Defrance, P.; Gottignies, P.; Vincent, J.; Investigators, S.I. New Engl. J. Med. 2010, 362, 779-789.

[21] Hurley, M.J; Jenner, P. Pharmacol. Ther. 2006, 111, 715-728.

[22] Li, W.; Ning, M.; Koh, K.H.; Kim, H.; Jeong, H. Drug Metab. Dispos. 2014, 42, 796-802.

[23] Runge-Morris, M. Chemico-Biol. Interactions. 1998, 109, 315-327.

[24] Fang, H.L.; Shenoy, S.; Duanmu, Z.; Kocarek, T.A.; Runge-Morris, M. Drug Metab. Disp. 2003, 31, 1378-1381.

[25] Zhou, T.; Chen, Y.; Huang, C.; Chen, G. J. Appl. Toxicol. 2012, 32, 804-809.

[26] Maiti, S.; Chen, G. Arch. Biochem. Biophysics. 2003, 418, 161-168.

[27] Chen, Y.; Huang, C.Q.; Zhou, T.Y.; Zhang, S.F.; Chen, G.P. J. Biochem. Mol. Toxicol. 2010, 24, 102-114.

[28] Maiti, S.; Chen, G.P. Drug Metab. Disp. 2003, 31, 637-644.

[29] Sidharthan, N.P.; Minchin, R.F.; Butcher, N.J. J. Biol. Chem. 2013, 288, 34364-34374.

[30] Zhou, T.Y.; Huang, C.Q.; Chen, Y.; Shanbhag, P.; Chen, G.P. Am. J. Pharmacol. Toxicol. 2010, 5, 125-132.

[31] Xu, J.J.; Wang, S.Y.; Chen, Y.; Chen, G.P.; Li, Z.Q.; Shao, X.Y.; Li, L.; Zhou, T.Y. Acta Pharmacol. Sin. 2014, 35, 889-898.

[32] Wojcikowski, J.; Golembiowska, K.; Daniel, W.A. Biochem. Pharmacol. 2008, 76, 258-267.

[33] Kocarek, T.A.; Duanmu, Z.; Fang, H.L.; Runge-Morris, M. Biochem. Pharmacol. 2008, 76, 1036-1046.

[34] Rajkowski, K.M.; Robel, P.; Baulieu, E.E. Steroids. 1997, 62, 427-436.

[35] Salman, E.D.; Kadlubar, S.A.; Falany, C.N. Drug Metab. Dispos. 2009, 37, 706-709.

[36] Chen, Y.; Zhang, S.; Zhou, T.; Huang, C.; McLaughlin, A.; Chen, G. Toxicol. Appl. Pharmacol. 2013, 268, 106-112.

Comparison of dopamine with levodopa in the induction of aryl sulfotransferases and estrogen sulfotransferase in rat liver

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 11

Recommended Articles

Metrics

Comments

[1]	Ling Yong, Ye Yao, Mengyi Han, Xiaoxue Yan, Qingyu Yao, Yuchen Guo, Junsheng Xue, Guoshu Chen, Tianyan Zhou. QAP21 reduces stemness and mobility of metastatic breast cancer cells involving D1DR activation [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(4): 289-305.
[2]	Junsheng Xue, Siyuan Wang, Fangran Hao, Xiuyun Tian, Hong Su, Liang Yang, Qiming An, Chunyi Hao, Tianyan Zhou. Dopamine increases the anti-cancer efficacy of sunitinib in the treatment of pancreatic cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(10): 689-700.
[3]	Liang Yang, Ye Yao, Yaoyao Feng, Wei Lu, Tianyan Zhou. Pharmacodynamic model of dopamine D1 receptor agonists in the treatment of breast cancer lung metastasis [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(1): 45-54.
[4]	Yaoyao Feng, Peili Jiao, Xiaoxue Yan, Zixi Xue, Ye Yao, Liang Yang, Daming Kong, Hong Su, Ling Yong, Guoshu Chen, Tianyan Zhou. Compound C17 inhibits the lung metastasis of breast cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(10): 716-727.
[5]	Yongfei Guo, Chen Wang, Wan Li, Ke Zhang, Hui Lei, Yi Sun, Xiaoping Pu, Xin Zhao. Neuroprotective effects of xanthone extract from Swertia punicea Hemsl against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of Parkinson’s disease [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(5): 357-365.
[6]	Fenfen Yin, Zhengrong Wu, Lifang Zheng, Hongyu Li, Beining Chen. Stability, cytotoxicity, and saturation effect of the free radical-scavenging cinnamic acid-dopamine hybrid antioxidants [J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(3): 148-155.
[7]	Liang Li, Zai-Quan Li, Han-Qing Li, Shan-Shan Bi, Jiao-Jiao Xu, Bo Li, Tian-Yan Zhou^, Wei Lu^. Absolute quantification of induced mRNA expression of CYP3A1 and CYP3A2 in rat liver using quantitative real time PCR assay [J]. , 2011, 20(6): 597-603.
[8]	Da-Long Zhao, Da-Wei Shen, Yu-Tao Chi, Fang Liu, Li-Bo Zou, Hai-Bo Zhu^*. Liriodendrin protects SH-SY5Y cells from dopamine-induced cytotoxicity [J]. , 2007, 16(4): 294-299.
[9]	XIAO Yan-li^*, DONG Zhi, FU Jie-min, ZHOU Qi-xin, LIAO Hong. Neuroprotective Effects of Modafinil on MPTP Mouse Model of Parkinson's Disease [J]. , 2003, 12(3): 148-153.
[10]	Qi-Qing Zhu, Zong-Ru Guo^*. Modeling of Dopamine D2 Receptor and its Agonist DOCK Analyses [J]. , 1998, 7(3): 115-120.
[11]	Jian-Jun Zhang, Xin-Yi Niu. Effects of MK-801 and Schizandrol A on DA/DOPAC Measured by Voltammetry in Ischemic Rat Striatum [J]. , 1992, 1(2): 54-58.